Arsenic Toxicology and Acute Promyelocytic Leukemia Therapy
This research community investigates the dual role of arsenic compounds: as a toxic environmental contaminant requiring risk assessment and as a therapeutic agent for treating acute promyelocytic leukemia.
The work centers on the mechanisms of arsenic-induced oxidative stress, DNA methylation changes, and signaling pathway disruptions in cancer cells. A significant portion of the literature focuses on the clinical application of arsenic trioxide and sodium arsenite in the treatment of acute promyelocytic and myeloid leukemia, including targeted therapy strategies and resistance mechanisms. Concurrently, the community develops analytical methods, such as inductively coupled plasma mass spectrometry, for detecting inorganic arsenic species in drinking water and biological samples to support exposure risk assessment.
Arsenic research constitutes the largest share of this community, accounting for 10.4% of all tracked arsenic studies and 16,994 papers within this group. The community publishes primarily in Blood, Environmental Health Perspectives, and Toxicology and Applied Pharmacology.
Recent work continues to focus on updating diagnostic and management guidelines for acute myeloid leukemia, including minimal residual disease consensus documents and clinical trials for targeted therapies like quizartinib and revumenib. Additionally, new research explores the use of organoarsenicals in cancer immunotherapy and the detection of toxic elements in food samples.